SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has expanded the applications of its Hemopurifier® platform technology to address voids in the infectious disease diagnostic market. The Aethlon Hemopurifier® is a first-in-class artificial adjunct to the immune system able to provide real-time capture of infectious viruses and immunosuppressive particles from the entire circulatory system. The device is a leading broad-spectrum treatment candidate for acute and chronic virus infections. Scientific techniques that established the therapeutic potential of the Hemopurifier® will be leveraged to introduce ultra-sensitive clinical and research diagnostic tools that offer significant potential for previously unrecognized revenue channels.
